DEA’s 7-OH Scheduling Action: What Bulk Kratom Buyers Need to Know

Concentrated 7-hydroxymitragynine (7-OH) products — not raw kratom leaf — are the subject of a federal scheduling action moving through the U.S. Drug Enforcement Administration (DEA) as of mid-2026. For B2B buyers who source bulk kratom leaf or powder, the distinction between “kratom” and “7-OH” is now a compliance question, not just a labeling detail.

The U.S. Food and Drug Administration (FDA) has published a public health notice on the topic, framing concentrated and synthetic 7-OH as an emerging opioid-related concern (Source: FDA, “Hiding in Plain Sight: 7-OH Products,” updated July 2026). This article summarizes what buyers need to know, in plain terms, and does not offer legal advice — buyers should confirm current status directly with the Federal Register or their own counsel before making sourcing or import decisions.

What Is 7-OH, and How Is It Different From Kratom Leaf?

7-hydroxymitragynine (7-OH) is a minor alkaloid that occurs naturally in trace amounts in the kratom plant (Mitragyna speciosa). Ordinary dried kratom leaf and powder contain only very small, naturally occurring levels of it.

The products at the center of the current federal action are different: concentrated or semi-synthetically enhanced 7-OH items — tablets, gummies, shots, dissolvable strips, and similar formats — sold at gas stations, convenience stores, smoke shops, and online (Source: DEA/HHS notices, July 2026). These are manufactured to contain 7-OH at levels far above what raw leaf naturally contains.

This distinction — natural trace-level leaf versus concentrated or synthetic extract — is the exact line regulators have drawn.

What the DEA and FDA Actually Announced

On July 1, 2026, the DEA filed two Notices of Intent, published in the Federal Register on July 6, 2026, signaling its intent to temporarily place substances into Schedule I of the Controlled Substances Act (CSA):

1. 7-hydroxymitragynine (7-OH) above a specified threshold — proposed at 0.05% by dry weight for the kratom plant itself, or 0.05% / 1 milligram per article for processed products such as extracts, concentrates, edibles, or pressed pills.
2. Three synthetic derivatives that do not occur naturally in kratom — mitragynine pseudoindoxyl, MGM-15, and MGM-16.

The agencies were explicit about scope: these actions are intended to target concentrated and synthetic 7-OH products, and are not intended to apply to natural kratom leaf containing only naturally occurring trace levels of 7-OH (Source: FDA, July 2026 update). Mitragynine — kratom’s primary alkaloid, and the one Indonesian export regulation already tests for — is not named in either notice.

By statute, a temporary scheduling order cannot take effect before August 5, 2026, and HHS ran a 30-day public comment period on the proposed threshold through July 31, 2026. As of early August 2026, the order had not yet been formally issued, though the DEA has stated it intends to act soon after the earliest eligible date. Because this is an active rulemaking process, buyers should check the Federal Register directly for the current status before relying on any specific date.

If and when issued, the temporary scheduling would remain in effect for up to two years, with a possible one-year extension, while a permanent scheduling review is considered.

Why This Matters for B2B Buyers Sourcing Bulk Kratom

For buyers purchasing raw kratom leaf or powder — the product category most bulk wholesale, private-label, and distribution buyers are actually sourcing — this action does not change the product’s federal legal status on its own, based on the scope described by DEA and HHS. But three practical issues follow directly from it:

• Documentation now matters more. Buyers should be able to show, via lab testing, that what they’re importing is natural leaf material with 7-OH at naturally occurring trace levels — not a concentrated or enhanced product.
• Category confusion is a real business risk. Media coverage of “kratom” and the “opioid epidemic” often does not distinguish between raw leaf and concentrated 7-OH extracts. Buyers and their downstream retail partners may need to actively communicate this distinction to avoid reputational spillover.
• State law is separate from federal law. Several states already restrict or ban 7-OH or kratom independently of federal scheduling status — Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin ban 7-OH products, and Tennessee and Kansas added restrictions effective July 1, 2026 (Source: state legislative trackers, 2026). Buyers reselling into the U.S. market need to check destination-state rules regardless of what happens federally.

What to Verify From Any Supplier Right Now

Before finalizing a bulk kratom order, buyers should ask suppliers to confirm the following:

How Borneohale Approaches This

Borneohale exports dried, milled kratom leaf and powder — not concentrated or synthetically enhanced extracts. Every shipment is tested via PT Sucofindo’s Laporan Surveyor process, which reports mitragynine content against Indonesia’s own regulatory thresholds (minimum 1.2% for green/white vein, 0.8% for red vein, per Permendag No. 5 of 2026), alongside heavy metal and microbiological testing. For a fuller walkthrough of how that documentation fits into a bulk order, see our sourcing guide for international wholesale buyers.

Buyers who need documentation addressing 7-OH levels specifically, or who want to discuss testing scope ahead of a bulk order, can raise this directly with the Borneohale team as part of the standard due-diligence process.

Conclusion

The current DEA and FDA actions target concentrated and synthetic 7-OH products, not natural kratom leaf, based on the scope both agencies have publicly described. For B2B buyers, the practical response is the same discipline that should already apply to any bulk kratom purchase: verify lab testing, confirm the product form, and check both federal and state-level rules for the destination market — rather than assuming any single announcement changes the legal status of the raw leaf product itself.

Buyers who want to discuss testing documentation, product specifications, or compliance questions related to this topic can reach the Borneohale team at info@borneohale.com or via our Contact page.

FAQ About 7-OH and Kratom Regulation

Does the DEA’s action ban kratom leaf?

Based on the scope described in the DEA and HHS notices, the action targets 7-OH above a specified threshold and three synthetic derivatives, not natural kratom leaf containing only trace levels of 7-OH. This is not legal advice; buyers should verify current status directly.

What is the 7-OH threshold being proposed?

As proposed in the DEA’s Notice of Intent, 0.05% by dry weight for the kratom plant, or 0.05% / 1 milligram per article for processed products like extracts and pressed pills. This figure is part of an active rulemaking process and could change before a final order is issued.

Is 7-OH scheduling already in effect?

As of early August 2026, no temporary scheduling order had been formally issued; the earliest possible effective date under the statute is August 5, 2026. Buyers should check the Federal Register for the current status rather than relying on this article’s publish date.

Does this affect Borneohale’s kratom leaf and powder exports?

Borneohale exports natural dried leaf and powder, tested for mitragynine content under Indonesian export regulation — not concentrated or synthetic 7-OH products. Buyers with specific documentation needs can raise them directly with the Borneohale team.

Do state laws matter separately from this federal action?

Yes. Several states restrict or ban 7-OH or kratom independently of federal scheduling status. Buyers reselling into the U.S. should check destination-state rules regardless of the federal outcome.